Tandem Diabetes (TNDM) Care announced publication by The New England Journal of Medicine of results from the company’s pivotal trial of Control-IQ+ automated insulin delivery technology in people with ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Hosted on MSN
Tandem Diabetes Care highlights potential for type 2 diabetes market growth with Control-IQ+
CEO John Sheridan highlighted that Tandem achieved over 20% growth for the third consecutive quarter, with record sales both in the U.S. and internationally. The company's operational focus on ...
GlobalData on MSN
FDA clears Tandem’s Control-IQ+ technology for type 2 diabetes
The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin ...
The next big thing on Tandem Diabetes Care’s technology slate is actually a very small thing. The Mobi insulin pump—which is the company's smallest device to date and, it claims, the smallest ...
“Ease of use is what drives adoption,” CEO John Sheridan explains to Bloomberg Intelligence about what can drive further insulin pump penetration. In this episode of Vanguards of Health Care, Sheridan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback